NCT05808192

De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 92 (actual)
• Sponsor: University of Rome Tor Vergata · Academic / Other
• Sex: All
• Age: 49 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

Detailed description

A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).

Conditions

• Single Transplant
• 5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

Interventions

Type	Name	Description
DRUG	Immunosuppressive	compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Timeline

• Start date: 2020-09-01
• Primary completion: 2022-02-01
• Completion: 2022-05-01
• First posted: 2023-04-11
• Last updated: 2023-04-11

Locations

1 site across 1 country: Italy